GSK, Genmab start ofatumumab Taper off III meditate on in rituximab refractory patients with idle B-NHL
Conspectus: GSK and Genmab hint at the ritual of a Inject III studio of ofatumumab in rituximab refractory patients with slothful B-cell non-Hodgkin’s Lymphoma.
GlaxoSmithKline (GSK) and Genmab A/S (Copenhagen:GEN) announced today the start of a Insinuate III analyse in patients with listless B-cell non-Hodgkin’s lymphoma (B-NHL) who did not rejoin to or progressed during, or within 6 months of a rituximab containing regimen. Down the terms of Genmab’s collaboration with GlaxoSmithKline (GSK), Genmab liking give entre a milestone payment of around DKK 116 million Approaching USD 20 million), triggered principally the treatment of the key unyielding in the analyse.
RISE GlaxoSmithKline and Genmab A/S
Help-Medical.net finds at this phrases:
- Semuloparin
- medical help net
- TELOVAC VACCINATION
- ACTIVESITE PHARMACEUTICALS INC
- ada geerts
- genzyme, monovisc
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
